SOPHiA GENETICS (NASDAQ:SOPH) Reaches New 52-Week High – Still a Buy?

SOPHiA GENETICS SA (NASDAQ:SOPH) shares hit a new 52-week high on Tuesday . The stock traded as high as $6.65 and last traded at $6.37, with a volume of 1935 shares trading hands. The stock had previously closed at $6.33.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $12 price target, suggesting meaningful upside from current levels and boosting sentiment around SOPHiA GENETICS’s longer-term growth story.
• Positive Sentiment: The same research note laid out an improving earnings path, with SOPHiA GENETICS expected to narrow losses in 2026-2027 and turn profitable by FY2028, while projecting stronger earnings in FY2029 and FY2030.
• Neutral Sentiment: The company announced it will report second-quarter 2026 results on August 4, which typically increases trading interest as investors position ahead of the earnings release. SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
• Neutral Sentiment: A media appearance featuring the CEO discussing how AI could personalize patient therapies reinforces the company’s AI-driven precision medicine narrative, but it is not a direct financial catalyst. SOPHiA GENETICS CEO says AI will personalize patient therapies
• Negative Sentiment: The analyst estimates still point to continued losses in the near term, including FY2026 EPS of ($0.58) and FY2027 EPS of ($0.20), which may temper enthusiasm despite the bullish target price.

Wall Street Analysts Forecast Growth

SOPH has been the topic of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. HC Wainwright began coverage on shares of SOPHiA GENETICS in a research report on Monday. They set a “buy” rating and a $12.00 target price on the stock. Finally, BTIG Research reaffirmed a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, SOPHiA GENETICS presently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

SOPHiA GENETICS Price Performance

The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. The stock’s 50-day moving average price is $5.34 and its 200 day moving average price is $5.06. The firm has a market cap of $536.90 million, a price-to-earnings ratio of -12.31 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The firm had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million. Equities research analysts predict that SOPHiA GENETICS SA will post -0.58 earnings per share for the current year.

Insider Buying and Selling at SOPHiA GENETICS

In other SOPHiA GENETICS news, Chairman Jurgi Camblong sold 8,500 shares of the stock in a transaction on Friday, July 10th. The stock was sold at an average price of $5.62, for a total transaction of $47,770.00. Following the completion of the transaction, the chairman directly owned 3,532,622 shares in the company, valued at $19,853,335.64. This represents a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO Abhimanyu Verma sold 5,285 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $5.10, for a total transaction of $26,953.50. Following the sale, the chief technology officer directly owned 192,171 shares of the company’s stock, valued at approximately $980,072.10. The trade was a 2.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 176,711 shares of company stock valued at $959,913 in the last quarter. 4.88% of the stock is currently owned by corporate insiders.

Institutional Trading of SOPHiA GENETICS

Hedge funds have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after buying an additional 5,432,871 shares during the period. Federated Hermes Inc. raised its stake in SOPHiA GENETICS by 16.4% during the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock worth $682,000 after buying an additional 31,000 shares during the period. Akre Capital Management LLC lifted its holdings in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in SOPHiA GENETICS by 24.7% in the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock valued at $148,000 after acquiring an additional 6,205 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS in the third quarter worth about $49,000. 31.59% of the stock is owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.